Urovant Sciences, a phase 3 biotech developing an acquired oral therapy for overactive bladder, raised $140 million by offering 10 million shares at $14, the low end of the range of $14 to $16. Urovant Sciences plans to list on the Nasdaq under the symbol UROV. J.P. Morgan, Jefferies and Cowen acted as lead managers on the deal.
